Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy

Nanoscale(2024)10.1039/d4nr01780cSource: DataRank Database

Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy is a research paper published in Nanoscale (2024). On theSindex it has a DataRank of 0. It has been cited 36 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access36 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 4.62)OA: hybridTopics (47)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Tongrui Liu,Lei Zhu ORCID,Lily Yang ORCID,Kory Wells ORCID

Live enrichment

PubMed:39257225 PMC:PMC12139611 OpenAlex:https://openalex.org/W4402306821

Common Fund

Grant: NIH R01CA261251

Common Fund

Grant: NIH R41CA247165

NCI NIH HHS

Grant: R01 CA261251

NCI NIH HHS

Grant: U01 CA151810

NCI NIH HHS

Grant: U01 CA198913

NCI NIH HHS

Grant: R41 CA247165

National Institutes of Health

Grant: 5R01CA261251-05

Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer

National Institutes of Health

Grant: 3R41CA247165-01A1S1

Tumor Stroma Breaking System for Efficient Delivery of Therapeutic Agents

FWCI

4.62

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://pubs.rsc.org/en/content/articlepdf/2024/nr/d4nr01780c

publisherhttps://pubs.rsc.org/en/content/articlepdf/2024/nr/d4nr01780c

publisherhttp://pubs.rsc.org/en/content/articlepdf/2024/NR/D4NR01780C

journalhttps://doi.org/10.1039/d4nr01780c

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39257225

Fields of Study

Nanoplatforms for cancer theranosticsNanoparticle-Based Drug DeliveryImmunotherapy and Immune Responses02 engineering and technology0210 nano-technologyHumansNeoplasmsT-Lymphocytes, CytotoxicNanoparticlesImmunotherapyTumor MicroenvironmentAnimalsImmunomodulating AgentsCancer Vaccines

MeSH Terms

Immunomodulating AgentsAnimalsHumansImmunotherapyNeoplasmsT-Lymphocytes, CytotoxicCancer VaccinesNanoparticlesTumor Microenvironment

Keywords

Cytotoxic T cellCancer immunotherapyImmunotherapyCancerNanoparticleCancer researchCancer cellCytotoxicityNanotechnologyChemistryMaterials scienceMedicineIn vitroBiochemistryInternal medicineImmunomodulating AgentsNeoplasmsTumor MicroenvironmentHumansNanoparticlesAnimalsCancer VaccinesArticleT-Lymphocytes, Cytotoxic

Sustainable Development Goals

SDG 0: Good health and well-being

Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy

FAIR Checklist

Authors (4)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)